References
- Selassie M, Sinha AC. The epidemiology and aetiology of obesity: a global challenge. Best Pract. Res. Clin. Anaesthesiol.25(1), 1–9 (2011).
- Klein S, Allison DB, Heymsfield SB et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am. J. Clin. Nutr.85(5), 1197–1202 (2007).
- ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ, van der Meer K. Preventing weight gain by lifestyle intervention in a general practice setting: three-year results of a randomized controlled trial. Arch. Intern. Med.171(4), 306–313 (2011).
- Kissane NA, Pratt JS. Medical and surgical treatment of obesity. Best Pract. Res. Clin. Anaesthesiol.25(1), 11–25 (2011).
- Despres JP, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler. Thromb. Vasc. Biol.28(6), 1039–1049 (2008).
- Jakobsen MU, Berentzen T, Sorensen TI, Overvad K. Abdominal obesity and fatty liver. Epidemiol. Rev.29, 77–87 (2007).
- Fabbrini E, Magkos F, Mohammed BS et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl Acad. Sci. USA106(36), 15430–15435 (2009).
- Fabbrini E, Tamboli RA, Magkos F et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology139(2), 448–455 (2010).
- Mulvihill EE, Huff MW. Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can. J. Cardiol.26(Suppl. A), 17A–21A (2010).
- Hooper L, Kroon PA, Rimm EB et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr.88(1), 38–50 (2008).
- Sato T, Koike L, Miyata Y et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res.62(4), 1025–1029 (2002).
- Li RW, Theriault AG, Au K et al. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci.79(4), 365–373 (2006).
- Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med.7(8), 941–946 (2001).
- Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol.72, 219–246 (2010).
- Saito T, Abe D, Sekiya K. Nobiletin enhances differentiation and lipolysis of 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun.357(2), 371–376 (2007).
- Miyata Y, Tanaka H, Shimada A et al. Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyflavonoids, nobiletin and tangeretin. Life Sci.88(13–14), 613–618 (2011).
- Mulvihill EE, Assini JM, Lee JK et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes60(5), 1446–1457 (2011).
- Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.28(7), 1225–1236 (2008).
- Lee YS, Cha BY, Saito K et al. Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice. Biochem. Pharmacol.79(11), 1674–1683 (2009).
- Roza JM, Xian-Liu Z, Guthrie N. Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Altern. Ther. Health Med.13(6), 44–48 (2007).